Phase II Study of Modified Triple Doublet Therapy in Women With Newly Diagnosed Mullerian Carcinoma
Status:
Completed
Trial end date:
2005-07-01
Target enrollment:
Participant gender:
Summary
Over the last few years several novel agents have been defined which are active in the
treatment of relapsed epithelial ovarian carcinoma. Many of these new agents seemed to have
mechanisms of action that are different from Carboplatin and taxol. This trial looks to
evaluate the effectiveness and toxicity of three sequential chemotherapy doublets in the
treatment of women with newly diagnosed ovarian, primary peritoneal or tubal carcinoma.